Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
1 hedge funds and large institutions have $0 invested in Acura Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $352K → $0 (-$352K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$352K |
ACUR Hedge Fund Activity: Q2 2019 in Review
1 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q2 2019, worth a combined $0 — down 100% from $352K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ACUR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Essex Woodlands Management, exiting entirely with an estimated $352K sold.
- 1 institutional investor held Acura Pharmaceuticals (ACUR) as of Q2 2019, down from 2 in Q1 2019.
- Funds reported $0 of Acura Pharmaceuticals stock for Q2 2019, down 100% quarter-over-quarter.
- 0 funds opened new Acura Pharmaceuticals positions in Q2 2019 and 1 closed out, a net change of -1 holder.
- The largest Acura Pharmaceuticals seller in Q2 2019 was Essex Woodlands Management, an estimated $352K sold.
Based on aggregated 13F filings for Q2 2019.